Quality of life in hypertensive patients treated with either carvedilol or enalapril

Blood Pressure

Volumn 5, Issue 1, 1996, Pages 41-49

  Ostergren J ^a   Storstein, L ^b   Karlberg, B E ^c   Tibblin, G ^d   Andersson, Dan ^e   Andersson, Håkan ^e   Bojestig, Mats ^e   Ekström, Nils Åke ^e   Hagströmer, Raoul ^e   Karlmar, Karl Erik ^e   Leszniewska, Danuta ^e   Lindström, Torbjörn ^e   Naeslund, Grels ^e   Nyström, Bo ^e   Oldne, Christer ^e   Treiberg, Berndt ^e   Wersäll, Jonas ^e   Wikland, Bo ^e   Åkeson, Jan Åke ^e   Öhman, Peter ^e   Nahoui, Rim ^b   Drottning, Per ^b   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ICIT   (Norway)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e NONE

Author keywords

Antihypertensive therapy; Carvedilol; Enalapril; Hypertension; Quality of life; Serum lipids; Side effects

Indexed keywords

CARVEDILOL; ENALAPRIL; HYDROCHLOROTHIAZIDE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; WELLBEING;

EID: 13344294385     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059609062105     Document Type: Article

References (23)

1. Kullman S. Svärdsudd K. Differences in perceived symptoms/quality of life in untreated hypertensive and normotensive men. Scand J Prim Health Care 1990; Suppl 1: 47-53.
2. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins D et al. The effects of antihypertensive therapy on quality of life. N Eng J Med 1986: 314: 1657-64.
3. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. N Eng J Med 1993:328:907-13.
4. Yue T-L, Cheng H-Y, Lysko PG et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Therap 1992; 263: 92-8.
5. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21: 221-7.
6. Tibblin G, Tibblin B, Peciva S, Kullman S, Svärdsudd K. "The Göteborg Quality of Life Instrument"-an assessment of well-being and symptoms among men born in 1913 and 1923-methods and validity. Scand J Prim Health Care 1990; Suppl 1: 33-8.
7. Seigler L, Wu W. Separation of serum high-density hpoprotein for cholesterol determination-precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41.
8. Eggertsen R, Sivertsson R, Andren L, Hansson L. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 1984; 2: 529-34.
9. Eggertsen R, Sivertsson R, Andren L, Hansson L. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 (Suppl 11): 45-58.
10. Heber ME, Brigden GS, Caruana MP, Lahiri A. Raftery EB. Carvedilol for systematic hypertension. Am J Cardiol 1987; 59: 400-5.
11. Leonetti g, Sampieri L, Cuspidi C, et al. Resting and postexercise hemodynamic effects of carvedilol, a betaadrenergic blocker and precapillary vasodilator in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 (Suppl 11): 94-6.
12. DuPont AG, Van der Niepen P, Taeymans Y. et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 (Suppl 11): 130-6.
13. Lund-Johansen P. Chronic hemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1992; 13: 281-6.
14. Langdon CG, Baxter GA, Young PH. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild to moderate essential hypertension. J Cardiovasc Pharmacol 1991; 18 (Suppl 4): 51-6.
15. Ollivier JP, Durier P, Busseire JL, Gayet JL. Safety and efficacy of once-daily carvedilol vs. twice-daily labetalol in mild to moderate hypertension. Eur J Clin Pharmacol 1990; 38 (Suppl 2): 164-6.
16. Lambert M, Luccioni R, Habib G, et al. Comparison of effectiveness and safety of carvedilol (25 mg once daily) versus labetalol (200 mg twice daily) in patients with mild to moderate hypertension using an ambulatory 24 hours Holier monitoring [Abstract]. Am J Hypertens 1991; 4-106A.
17. Hall J, Prescott RI, Hallman RJ, Dixon S, Harvey RE, Ball SG. Carvedilol, a new multiple action vasodilatory beta-blocker for the management of essential hypertension: a comparison with slow-release nifedipine and with atenolol. J Cardiovasc Pharmacol 1991; 18 (Suppl 4): 35-8.
18. Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo JP. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990; 4: 217-25.
19. Malani PL, Strocchi E, Cervi V et al. The metabolic effects of enalapril. Clin Exp Hypertens (A) 1987; 9: 675-9.
20. Goto Y, Tamachi H, Fusegawa Y et al. Effects of Carvedilol on serum lipids in patients with essential hypertension. J. Cardiovasc Pharmacol 1991; 18 (Suppl 4): 45-50.
21. Johnson BF. The relevance of plasma lipid changes with cardiovascular drug therapy. Med Clin North Am 1989; 73: 449-73.
22. White MA. Alpha blockers. Antihypertensives whose positive metabolic profile with regard to hyperinsulinaemia and lipid metabolism cannot be ignored. J. Intern Med 1991; 229 (Suppl 2): 113-7.
23. Hylander B, Eliasson K, Nilsson-Ehle P et al. Effects of long-term therapy with labetalol on hpoprotein metabolism in patients with mild hypertension. Acta Med Scand 1985; 218; 51-5.